Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMycelx Di Regulatory News (MYX)

Share Price Information for Mycelx Di (MYX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 55.50
Bid: 53.00
Ask: 58.00
Change: 0.00 (0.00%)
Spread: 5.00 (9.434%)
Open: 55.50
High: 55.50
Low: 55.50
Prev. Close: 55.50
MYX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

30 May 2017 13:19

RNS Number : 5853G
MyCelx Technologies Corporation
30 May 2017
 

MYCELX Technologies Corporation

("MYCELX" or the "Company") (AIM: MYX)

30 May 2017

 

 

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). This inside information is now considered to be in the public domain.

 

Grant of Share Option to Chief Financial Officer

 

On 26 May 2017 Ms. Slayton was awarded the following options over the Company's common shares of US$0.025 each ("Common Shares") under the MYCELX Omnibus Performance Incentive Plan ("Plan"):

 

Name

Number of share options granted

Exercise price

Total number of share options held following this notification

Total number of share options as % of current issued share capital

Kimberly Slayton

30,000

US$0.75*

130,000

0.69%

 

Ms. Slayton holds no Common Shares in the issued capital of the Company.

 

Grant of Share Option to Chief Business Development Officer

 

The Company further announces that Mark Mixon, Chief Business Development Officer, was granted an option on 26 May 2017 under the Plan over 35,000 Common Shares. The grant to Mr. Mixon was as follows:

 

Name

Number of share options granted

Exercise price

Total number of share options held following this notification

Total number of share options as % of current issued share capital

Mark Mixon

35,000

US$0.75*

300,204

1.60%

 

In addition, following this transaction, Mr. Mixon continues to be interested in 10,000 Common Shares, representing 0.05 per cent of the present issued capital of the Company, which he holds as a custodian.

 

Grant of Share Option to Chief Executive Officer

 

The Company further announces that Connie Mixon, Chief Executive Officer, was granted an option on 26 May 2017 under the Plan over 40,000 Common Shares. The grant to Ms. Mixon was as follows:

 

Name

Number of share options granted

Exercise price

Total number of share options held following this notification

Total number of share options as % of current issued share capital

Connie Mixon

40,000

US$0.75*

203,017

1.08%

 

 

Following this award, Connie Mixon, Chief Executive Officer and spouse of Mr. Mixon is interested in an aggregate (including the interests of Mr. Mixon) of 991,211 Common Shares, representing 5.28 per cent of the present issued capital of the Company, and in options over an aggregate (including the interests of Mr. Mixon) of 503,221 Common Shares, representing 2.68 per cent of the present issued capital of the Company.

 

The aggregate number of Common Shares held by Ms. Mixon also includes (a) 150,000 shares held by limited liability companies controlled by Ms. Mixon; and (b) 202,646 shares held by or on behalf of Ms. Mixon's children.

 

The above grants formed part of wider grants of 205,000 options to employees across the Company, on the same date, representing 1.09% of the current issued share capital.

 

The share options granted on 26 May 2017 will vest as to 50% on 31 December 2017 and 50% on 31 December 2018, and must be exercised prior to the tenth anniversary of the date of grant, subject to the restrictions on dealing under the Company's share dealing code.

 

Following the above grants, a total of 1,192,042 share options have been granted to directors and employees and are currently outstanding, representing 6.35% of the issued share capital of 18,770,117 Common Shares. *Based on the closing mid-market price of the Company's Common Shares at 26 May 2017, and the closing US/£ exchange rate at that date.

 

For further information please contact:

 

MYCELX Technologies Corporation

Connie Mixon, CEO

Kim Slayton, CFO

 

Tel: +1 888 306 6843

Cantor Fitzgerald Europe - NOMAD and Broker

Andrew Craig

Richard Salmond

 

Tel: +44 20 7894 7000

Celicourt Communications

Mark Antelme

Joanna Boon

 

Tel: +44 20 7520 9266

 

The relevant notifications set out below are provided in accordance with the requirements of Article 19 of the EU Market Abuse Regulation (No. 596/2014).

Notification of transactions of persons discharging managerial responsibility or connected persons

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Connie Mixon

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Director

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Mycelx Technologies Corporation

b)

 

LEI

 

 

213800UJZINIK2VD1G48

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

 

Common shares of US$0.025

 

USU624551078

 

 

b)

 

Nature of the transaction

 

 

Grant of share option to Connie Mixon under the Mycelx Omnibus Performance Incentive Plan

 

 

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

 

US$0.75

 

40,000

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

 

 

 

n/a

 

 

n/a

 

 

e)

 

Date of the transaction

 

 

2017/05/26

f)

 

Place of the transaction

 

 

Grant of the options occurred outside a trading venue.

 

 

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Connie Mixon

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Director

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Mycelx Technologies Corporation

b)

 

LEI

 

 

213800UJZINIK2VD1G48

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

 

Common shares of US$0.025

 

USU624551078

 

 

b)

 

Nature of the transaction

 

 

Grant of share option to spouse, Mark Mixon, under the Mycelx Omnibus Performance Incentive Plan

 

 

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

 

US$0.75

 

35,000

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

 

 

 

n/a

 

 

n/a

 

 

e)

 

Date of the transaction

 

 

2017/05/26

f)

 

Place of the transaction

 

 

Grant of the options occurred outside a trading venue.

 

 

 

 

Notes to Editors

MYCELX is a revolutionary oil-free water technology company solving the world's toughest oil removal problems in the oil and gas industry. The systems are based upon scientific breakthrough for a completely different approach to permanent oil removal. The Company created the patented MYCELX polymer using innovative molecular cohesion for removing oil from water far beyond what conventional systems have ever achieved. MYCELX systems remove oil to critically low levels in a much smaller physical footprint than conventional systems and in a virtually fail-safe process.

www.mycelx.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHLLFLFETIIVID
Date   Source Headline
24th Apr 20247:00 amRNSBusiness Update
11th Apr 20247:00 amRNSEPA Publishes National Drinking Water Standards
26th Mar 20243:30 pmRNSDirector Dealing
26th Mar 20247:00 amRNSDirector Dealing
22nd Mar 20247:00 amRNSDirector Dealing
21st Mar 20247:00 amRNSDirector Dealing
18th Mar 20247:00 amRNSGrant of Share Options to Chief Financial Officer
4th Mar 20247:00 amRNSSaudi Arabia Business Operation Sale Completion
22nd Feb 20247:02 amRNSTrading Update
22nd Feb 20247:00 amRNSSaudi Arabia Business Operation Sale
21st Nov 20237:00 amRNSContract Update
16th Nov 20237:00 amRNSTrading Update
26th Sep 20233:10 pmRNSResult of Annual Meeting
20th Sep 20237:00 amRNSHalf Year Results Statement
11th Jul 20237:00 amRNSContract Award
5th Jul 20233:28 pmRNSHolding(s) in Company
3rd Jul 20232:37 pmRNSContract Award & PFAS Update
21st Jun 20237:00 amRNSMailing of AR and Notice of 2023 Annual Meeting
18th May 20237:00 amRNSFinal Results for the Year Ending 31 December 2022
12th May 20237:00 amRNSHolding(s) in Company
17th Apr 20237:00 amRNSSuccessful leach testing of PFAS media
14th Mar 20234:50 pmRNSClosure of Restricted Stock Line
8th Mar 20237:00 amRNSPilot Testing Agreement for PFAS Remediation
13th Feb 20237:00 amRNSOperational Update
31st Jan 20237:00 amRNSTrading Update
24th Jan 20237:00 amRNSContract Secured for PFAS Remediation System
8th Dec 20227:00 amRNSTrading Update
27th Sep 20227:00 amRNSHalf Year Results Statement
15th Sep 20227:00 amRNSTrading Update
6th Sep 20222:30 pmRNSHolding(s) in Company
30th Aug 20227:00 amRNSNew Project Awards and Operations Update
13th Jul 20223:32 pmRNSResult of Annual Meeting
13th Jun 20227:00 amRNS2021 Annual Report & Notice of 2022 Annual Meeting
17th May 20227:00 amRNSFinal Results for Year Ending 31 December 2021
3rd May 20227:00 amRNSDirector/PDMR Shareholding
3rd May 20227:00 amRNSChange of Main Office Address
23rd Mar 20229:17 amRNSTR1
21st Mar 20225:56 pmRNSBroker Option
16th Mar 20224:09 pmRNSHolding(s) in Company
11th Mar 20221:10 pmRNSDealings by Directors
11th Mar 20227:00 amRNSProposed Placing and Subscription
11th Feb 20227:00 amRNSTrading Update
2nd Feb 202211:07 amRNSHolding(s) in Company
25th Jan 20227:00 amRNSSuccessful Trial of PFAS Remediation System
10th Jan 20227:00 amRNSAward of Green Economy Mark
23rd Nov 20212:36 pmRNSHolding(s) in Company
11th Nov 202111:51 amRNSDealings by Directors
9th Nov 20214:42 pmRNSDirector/PDMR Shareholding
5th Nov 20217:00 amRNSDirector/PDMR Shareholding
28th Oct 20214:34 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.